Dr. Drevs at Work
SanaFontis Care

Clinical Studies

It is one of the major objectives of the Cancer Hospital SanaFontis to make new and promising therapies available to patients as fast as possible. For that purpose we have established a clinical study centre in which new drugs for tumours are being developed. Both out- and in-patients have the option to participate in studies that investigate innovative therapies, provided the patients can be expected to benefit from the treatment and there are no further therapy options open to them.

Advanced solid tumors

Multitarget: Phase I Study to Assess the Safety, Tolerability and Pharmaco-kinetics of Daily Oral Doses of AZD 2171 (20, 30 or 45 mg) when Co administered with Daily Oral Doses of AZD 0530 (125 mg or 175 mg) in Patients with Advanced Solid Tumours.

AMT  I: Phase II / III clinical trial  to evaluate the Clinical Benefit Response in cancer patients with advanced disease treated with the Auron Misheil Therapy (AMT) vs. Placebo.

Silence: A phase I study with Atu027 in subjects with advanced solid tumors.

Advanced liver cancer

AMT IIa: Phase II clinical trial to evaluate the efficacy and safety in patients with advanced primary HCC.

Advanced pancreatic cancer

AMT IIb: Phase II clinical trial to evaluate the efficacy and safety in patients with advanced pancreatic cancer.

Advanced colorectal cancer

AMT IIc: Phase II clinical trial to evaluate the efficacy and safety in patients with advanced colorectal cancer.

Immatics: Phase I-II study to investigate the effectiveness, safety, and immunogenecity of a monotherapy with intradermal IMA910 plus GM-CSF following pretreatment with low dose cyclo-phosphamide in advanced colorectal carcinoma patients who have successfully completed a 12 week first-line treatment with oxaliplatin-based chemotherapy.

Mantle cell lymphoma

Velcade: Phase III Study of the Combination of Rituximab, Cyclophos-phamide, Doxorubicin, VELCADE, and Prednison(VcR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Patients With Newly Diagnosed Mantle Cell Lymphoma who are not Eligible for a Bone Marrow Transplant.

Non small cell lung cancer

ATTRACT 2: Phase III Study of ASA404 in Combination with Docetaxel in Second –Line Treatment of patients with Advanced or Metastatic (Stage IIIb/IV) Non small cell lung Cancer (NSCLC).

Osteosarcoma

EURAMOS1: Treatment protocol for resectable osteosarcoma based on histological response to chemotherapy.

EURO-B.O.S.S.: Treatment protocol for highly malignant spindle cell sarcoma in patients over 40 years.

Ewing tumor

EURO-E.W.I.N.G.: Treatment protocol for Ewing Tumour.

Breakthrough pain

Pain: Phase III to evaluate Nasal Transmucosal Fentanyl Citrate (NTFC) vs oral morphine sulphate (OMS) for the treatment of breakthrough pain in cancer patients.

Solid tumors

Wermut: Anwendungsbeobachtung zur Wirksamkeit von Wermut bei Krebspatienten mit ungewollten Gewichtsverlust.

Metastatic gastric cancer

Imclone: Phase III Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric Cancer of Gastroesophageal Junction Adeno-carcinoma Following Disease Progression on First–Line Platinum – or Fluoropyrimidine-Containing Combination Therapy.